{
    "symbol": "SDGR",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-04 20:31:02",
    "content": "  I'd like to remind you that during today's call, management will make statements related to our business that are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our future financial performance, our outlook for the full year 2022 and for the third quarter ending September 30, 2022, our strategic plans to accelerate the growth of our software business and advance our collaborative and internal drug discovery programs, the timing of potential IND submissions and the initiation of clinical trials for our internal drug discovery programs, risks related to the COVID-19 pandemic, our expectations related to the use of our cash, cash equivalents and marketable securities as well as our future operating expenses."
}